F-star Therapeutics, Inc.
π¬π§United Kingdom
- Country
- π¬π§United Kingdom
- Ownership
- Public, Subsidiary
- Established
- 2006-01-01
- Employees
- 88
- Market Cap
- -
- Website
- http://www.f-star.com
Evaluating the Safety and Efficacy of Inarigivir in Non-cirrhotic Treatment Naive Subjects Infected With Hepatitis B Virus
Phase 2
Terminated
- Conditions
- Interventions
- First Posted Date
- 2019-08-16
- Last Posted Date
- 2020-07-21
- Lead Sponsor
- F-star Therapeutics, Inc.
- Target Recruit Count
- 5
- Registration Number
- NCT04059198
- Locations
- ππ°
Queen Mary Hospital, Hong Kong, Hong Kong Island, Hong Kong
ππ°Prince of Wales Hospital, Sha Tin, New Territories, Hong Kong
Evaluating the Safety and Efficacy of Inarigivir in Non-cirrhotic, Hepatitis B e Antigen-negative Subjects Infected With HBV Virus and Receiving or Stopping Treatment With a NUC Inhibitor
Phase 2
Terminated
- Conditions
- Interventions
- First Posted Date
- 2019-07-17
- Last Posted Date
- 2020-07-22
- Lead Sponsor
- F-star Therapeutics, Inc.
- Target Recruit Count
- 64
- Registration Number
- NCT04023721
- Locations
- π¨π¦
LAIR Centre, Vancouver, British Columbia, Canada
π¨π¦GI Research Institute, Vancouver, British Columbia, Canada
π¨π¦University of Calgary, Calgary, Alberta, Canada
Evaluating the Effects of Inarigivir on Immune Response and Viral Markers in Chronic Hepatitis B Patients
- First Posted Date
- 2019-04-30
- Last Posted Date
- 2020-04-29
- Lead Sponsor
- F-star Therapeutics, Inc.
- Target Recruit Count
- 8
- Registration Number
- NCT03932513
- Locations
- πΈπ¬
National University Hospital, Singapore, Singapore
A Fixed-Sequence, Drug-Drug Interaction Study Between Multiple Oral Doses of Inarigivir Soproxil and a Single Oral Dose of Midazolam in Healthy Subjects
- First Posted Date
- 2018-04-10
- Last Posted Date
- 2020-10-08
- Lead Sponsor
- F-star Therapeutics, Inc.
- Target Recruit Count
- 17
- Registration Number
- NCT03493698
- Locations
- π³π±
University Medical Center Groningen, Groningen, Netherlands
A Study Evaluating the Safety, Pharmacokinetics, and Antiviral Efficacy of SB 9200 in Subjects Infected With Chronic HBV
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2016-04-26
- Last Posted Date
- 2020-02-11
- Lead Sponsor
- F-star Therapeutics, Inc.
- Target Recruit Count
- 80
- Registration Number
- NCT02751996
- Locations
- π¨π³
Spring Bank Pharma Research Site, Taoyuan County, Taiwan
π°π·Spring Bank Pharma Research site, Seoul, Korea, Republic of
π°π·Spring Pharma Research Site, Chuncheon-si, Gangwon-do, Korea, Republic of
Β© Copyright 2024. All Rights Reserved by MedPath